MYGN Q3 2019 Earnings — Myriad Genetics, Inc. Revenue & Financial Results | Market Cap Arena

MYGNMyriad Genetics, Inc.

$454M

Q3 2019 Earnings

Healthcare Medical - Diagnostics & Research

Income Statement

Revenue

$186M-7.9% YoY

Gross Profit

$137M73.3% margin

Operating Income

-$21M-11.2% margin

Net Income

-$21M-11.1% margin

EPS (Diluted)

$-0.28

QoQ Revenue Growth

-13.5%

Cash Flow

Operating Cash Flow

$16M

Free Cash Flow

$14M

Stock-Based Comp.

$9M

Balance Sheet

Total Assets

$1.6B

Total Liabilities

$517M

Stockholders' Equity

$1.1B

Cash & Equivalents

$90M

Year-over-Year Comparison

Metric	Current	Year Ago	Change
Revenue	$186M	$202M	-7.9%
Gross Profit	$137M	$153M	-10.5%
Operating Income	-$21M	$1M	-1841.7%
Net Income	-$21M	-$700,000	-2842.9%

Revenue Segments

Diagnostics

$170M91%

All Other Segments

$16M9%

Geographic Segments

UNITED STATES

$175M94%

Non Us

$12M6%